NASDAQ:CMRXChimerix Stock Price, Forecast & News

Chimerix's stock was trading at $1.44 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, CMRX shares have increased by 129.9% and is now trading at $3.31.
View which stocks have been most impacted by Coronavirus.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Chimerix in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Chimerix.

Chimerix is scheduled to release its next quarterly earnings announcement on Monday, August 10th 2020.
View our earnings forecast for Chimerix.

Chimerix will be holding an earnings conference call on Monday, August 10th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Chimerix Inc (NASDAQ:CMRX) posted its earnings results on Thursday, May, 7th. The biopharmaceutical company reported ($0.17) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.15) by $0.02. The biopharmaceutical company had revenue of $1.24 million for the quarter, compared to analysts' expectations of $1.50 million. Chimerix had a negative return on equity of 34.16% and a negative net margin of 923.87%.
View Chimerix's earnings history.

1 equities research analysts have issued twelve-month price objectives for Chimerix's shares. Their forecasts range from $7.00 to $7.00. On average, they expect Chimerix's stock price to reach $7.00 in the next year. This suggests a possible upside of 111.5% from the stock's current price.
View analysts' price targets for Chimerix.

News coverage about CMRX stock has been trending positive recently, according to InfoTrie Sentiment Analysis. The research group ranks the sentiment of news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Chimerix earned a news sentiment score of 2.1 on InfoTrie's scale. They also gave media coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the immediate future.
View the latest news about Chimerix.

Chimerix saw a increase in short interest during the month of July. As of July 31st, there was short interest totaling 1,250,000 shares, an increase of 5.0% from the July 15th total of 1,190,000 shares. Based on an average daily volume of 1,080,000 shares, the days-to-cover ratio is currently 1.2 days. Approximately 2.7% of the shares of the stock are short sold.
View Chimerix's Current Options Chain.

Some companies that are related to Chimerix include Cara Therapeutics (CARA), Morphic (MORF), Omeros (OMER), Endo International (ENDP), Vectura Group (VEGPF), ORIC Pharmaceuticals (ORIC), Dynavax Technologies (DVAX), Nkarta (NKTX), Legend Biotech (AMTI), Assembly Biosciences (ASMB), Akouos (AKUS), ZIOPHARM Oncology (ZIOP), Passage Bio (KROS), ImmunoGen (IMGN) and Tricida (TCDA).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Chimerix investors own include Melinta Therapeutics (MLNT), Synergy Pharmaceuticals (SGYP), Immunomedics (IMMU), Novavax (NVAX), Inovio Pharmaceuticals (INO), SLS International (SLS), Wynn Resorts (WYNN), Gilead Sciences (GILD), Opko Health (OPK) and Sorrento Therapeutics (SRNE).

Chimerix trades on the NASDAQ under the ticker symbol "CMRX."

Chimerix's stock is owned by a number of retail and institutional investors. Top institutional investors include Russell Investments Group Ltd. (0.10%), Vanguard Capital Wealth Advisors (0.05%), SG Americas Securities LLC (0.04%), UBS Group AG (0.03%) and Marquette Asset Management LLC (0.03%). Company insiders that own Chimerix stock include Fred A Middleton, Garrett Nichols, Martha J Demski, Michael A Sherman, Michael T Andriole and Robert J Meyer.
View institutional ownership trends for Chimerix.

CMRX stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG, and Marquette Asset Management LLC.
View insider buying and selling activity for Chimerix.

CMRX stock was bought by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Vanguard Capital Wealth Advisors, and SG Americas Securities LLC. Company insiders that have bought Chimerix stock in the last two years include Fred A Middleton, Martha J Demski, Michael A Sherman, Michael T Andriole, and Robert J Meyer.
View insider buying and selling activity for Chimerix.

Shares of CMRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of CMRX stock can currently be purchased for approximately $3.31.

Chimerix has a market capitalization of $204.99 million and generates $12.52 million in revenue each year. The biopharmaceutical company earns $-112,580,000.00 in net income (profit) each year or ($0.86) on an earnings per share basis. Chimerix employs 82 workers across the globe.

The official website for Chimerix is www.chimerix.com.

Chimerix's mailing address is 2505 MERIDIAN PARKWAY SUITE 100, DURHAM NC, 27713. The biopharmaceutical company can be reached via phone at 919-806-1074 or via email at [email protected]